Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial

Quality of life ( QOL) was studied in gastric cancer patients treated on a randomised, controlled trial comparing D1 ( level 1) with D3 ( levels 1, 2 and 3) lymphadenectomy. A total of 221 patients were randomly assigned to D1 ( n = 110) and D3 ( n = 111) surgery. Quality-of-life assessments included functional outcomes ( a 14-item survey about treatment-specific symptoms) and health perception ( Spitzer QOL Index) was performed before and after surgery at disease-free status. Patients suffered from irrelative events such as loss of partners was excluded thereafter. Main analyses were done by intention-to-treat. Thus, 214 D1 ( 106/110 = 96.4%) and D3 ( 108/111 = 97.3%) R0 patients were assessed. Longitudinal analysis showed that functional outcomes decreased at 6 months after surgery and increased over time thereafter, while health perceptions increased over time in general. On the basis of linear mixed model analyses, patients having total gastrectomy, advanced cancer and hemipancreaticosplenectomy, but not complications had poorer QOL than those without. D1 and D3 patients showed no significant difference in QOL. The results suggest that changes of QOL were largely due to scope of gastric resection, disease status and distal pancreaticosplenectomy, rather than the extent of lymph node dissection. This indicates that nodal dissection can be performed for a potentially curable gastric cancer.